Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.
Shanghai Junshi Biosciences Co., Ltd. has announced a capital increase agreement involving its non-wholly owned subsidiary, JunTop Biosciences, and Shanghai Tanying Investment Partnership. This transaction, which is classified as a related party transaction under PRC laws, does not constitute a connected transaction under Hong Kong’s Listing Rules. The agreement signifies a strategic move to bolster financial resources, potentially enhancing the company’s market position and operational capabilities.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biosciences industry. The company focuses on the development and commercialization of innovative therapies, particularly in the field of immuno-oncology.
Average Trading Volume: 13,139,562
Technical Sentiment Signal: Buy
Current Market Cap: HK$42B
For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.